Clinic Roundup

KemPharm Inc., of North Liberty, Iowa, reported positive results from a Phase I trial of opioid-based drug candidate KP201, showing that it is cleaved in man as predicted, releasing the active pharmaceutical compound, hydrocodone, into the bloodstream at amounts equivalent to the reference listed drug. KP201 also could not be detected in systemic circulation, indicating that minimal additional studies are warranted to determine impact of KP201 exposure on the body. KP201 is composed of hydrocodone chemically bound to a ligand.